At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

Aug 5 - Pfizer (NYSE:PFE) heads into its Q2 earnings release amid growing investor caution. Analysts expect revenue around ...

Global pharmaceutical company Pfizer (NYSE:PFE) announced in Q2 CY2025, with sales up 10.3% year on year to $14.65 billion.

Pfizer PFE reported second-quarter 2025 adjusted earnings per share of 78 cents, which comprehensively beat the Zacks ...

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

On the company’s Q2 earning call, Pfizer (PFE) noted that the company’s guidance “absorbs the impact of the currently imposed ...

Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 ...

Pfizer, the U.S.-based pharmaceutical giant, revealed its second-quarter financial results on Tuesday, showcasing a robust 10 ...

Pfizer stock rises after a strong Q2, boosted by cost savings, pipeline progress, and an upgraded 2025 profit outlook.

Pfizer (PFE) stock is rising after the company reported strong second-quarter earnings and lifted its full-year forecast ...

Pfizer Inc. (NYSE:PFE) will release earnings results for the second quarter before the opening bell on Tuesday, Aug. 5.